Search Results
Your search for ,iII matches 9601 pages
Showing 1851 - 1900Telephone-Based Weight Loss Intervention for Patients With Breast Cancer and Overweight/Obesity
A randomized study by Jennifer A. Ligibel, MD, Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School, evaluating the impact of a telephone-based weight loss intervention in...
Medicaid Expansion Associated With a Reduction in Mortality for Black Patients With Gastrointestinal Cancers
Studies showed that racial minorities experience disparities in access to cancer treatment and survival. In an effort to improve access to care for disadvantaged populations, the Affordable Care Act provided funding to states to expand Medicaid eligibility criteria and provide coverage to...
Luspatercept Improves Reliance on Blood Transfusions for Patients With Lower-Risk MDS
Patients with lower-risk myelodysplastic syndromes (MDS) who received luspatercept to treat anemia instead of erythropoiesis-stimulating agents (ESAs)—the current standard of care—needed fewer blood transfusions and clinic visits. These findings from the phase III COMMANDS trial were presented by...
Adding Pembrolizumab to Chemotherapy May Improve Survival in Patients With Advanced Cervical Cancer
Adding the PD-1 inhibitor pembrolizumab to chemotherapy, with or without bevacizumab, improved overall survival and progression-free survival in patients with persistent, recurrent, or metastatic cervical cancer, regardless of whether the cancer expressed PD-L1. These findings from the KEYNOTE-826...
Highlighting Progress in Myeloma Treatment: POLLUX Trial Final Overall Survival Results With Daratumumab-Based Therapy
The updated results of the POLLUX trial, reported in the Journal of Clinical Oncology by Dimopoulos and colleagues and in this issue of The ASCO Post, showed significantly improved overall survival with daratumumab plus lenalidomide/dexamethasone (DRd) vs Rd in patients with previously treated...
NOVA: Final Analysis Confirms No Significant Overall Survival Benefit for Maintenance Niraparib in Recurrent Ovarian Cancer
After resolving missing survival data in the phase III ENGOT-OV16/NOVA trial, no statistically significant difference in overall survival was found for patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the PARP inhibitor niraparib, investigators...
Expert Point of View: Amanda Nickles Fader, MD
Amanda Nickles Fader, MD, Professor of Gynecology and Obstetrics, Professor of Oncology, and Vice Chair of Gynecologic Surgical Operations at Johns Hopkins Health System, Baltimore, provided her thoughts on GOG 3026 for The ASCO Post. Dr. Fader applauded the investigators and the Gynecologic...
GOG 3026: Durable Responses With Ribociclib Plus Letrozole in Low-Grade Serous Ovarian Cancer
In patients with recurrent low-grade serous ovarian cancer, treatment with ribociclib plus letrozole was not only active, but led to outcomes that are comparable to those achieved with current agents—with a particularly striking 19-month duration of response—according to Brian M. Slomovitz, MD,...
GOG 258 Final Results: No Improvement in Survival by Adding Radiotherapy to Chemotherapy in Advanced Endometrial Cancer
The long-running randomized NRG Oncology GOG-258 clinical trial failed to identify an overall survival benefit with adjuvant chemoradiotherapy vs chemotherapy alone in any subgroup of patients with locally advanced endometrial cancer. After a median follow-up of 112 months, the hazard ratio for...
IMbrave050 Trial: Adjuvant Regimen of Atezolizumab Plus Bevacizumab in Resectable Hepatocellular Carcinoma
Adjuvant treatment with the combination of atezolizumab and bevacizumab achieved a statistically significant and clinically meaningful improvement in recurrence-free survival compared with active surveillance alone in patients with high-risk hepatocellular carcinoma following curative-intent...
Organizations Team Up to Improve Cancer Care in Rural Appalachia
The Appalachian Community Cancer Alliance (ACCA) has launched a lung cancer screening initiative to improve cancer care in rural Appalachia. Home to nearly 26 million people, the Appalachian region includes all of West Virginia and parts of 12 other states, and it has a 10% higher cancer mortality...
Assay Prediction of pCR in Patients With HER2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
In an analysis reported in JAMA Oncology, Waks et al found that the HER2DX assay performed well in predicting the likelihood of pathologic complete response (pCR) in patients with early HER2-positive breast cancer receiving de-escalated neoadjuvant treatment with paclitaxel, trastuzumab, and...
First-Line Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients With CLL
In the phase III GAIA–CLL13 trial reported in The New England Journal of Medicine, Barbara Eichhorst, MD, and colleagues found better outcomes with venetoclax plus obinutuzumab and venetoclax, obinutuzumab, and ibrutinib compared with chemoimmunotherapy as first-line treatment in fit patients with ...
HPV Self-Collection Kits May Increase Cervical Cancer Screenings Among Underscreened, Underserved Patients
Researchers have found that mailing human papillomavirus (HPV) self-collection kits in addition to offering scheduling assistance to underscreened, underserved patients may increase the rate of cervical cancer screenings compared with scheduling assistance alone, according to a new study published...
Addition of Bevacizumab to Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer
As reported in The New England Journal of Medicine by Prager et al, the phase III SUNLIGHT trial has shown prolonged overall survival with the addition of bevacizumab to trifluridine/tipiracil (FTD-TPI) in previously treated patients with metastatic colorectal cancer. As stated by the...
Patient-Reported Outcomes From the NRG Oncology/RTOG 0815 in Intermediate-Risk Prostate Cancer
In an analysis of the phase III NRG Oncology/RTOG 0815 study reported in the Journal of Clinical Oncology, Benjamin Movsas, MD, and colleagues found few differences in patient-reported outcomes among patients with intermediate-risk prostate cancer receiving short-term total androgen suppression...
Addition of Short-Term ADT to Dose-Escalated Radiotherapy in Intermediate-Risk Prostate Cancer
As reported in the Journal of Clinical Oncology by Daniel J. Krauss, MD, and colleagues, the phase III NRG Oncology/RTOG 0815 study showed no significant improvement in overall survival with the addition of short-term androgen-deprivation therapy (ADT) to dose-escalated radiotherapy in patients...
Cabozantinib in Combination With Nivolumab and Ipilimumab May Slow Progression of Advanced Renal Cell Carcinoma
The targeted kinase inhibitor cabozantinib plus a two-drug immunotherapy combination of nivolumab and ipilimumab may be capable of slowing cancer progression in patients with advanced renal cell carcinoma who received no prior lines of therapy, according to a study published by Choueiri et al in...
Adding Azacitidine to Standard Chemotherapy May Be Effective for Patients With PTCL-TFH
Researchers have found that azacitidine may be capable of increasing the effectiveness of chemotherapy and aiding nearly 90% of patients who had peripheral T-cell lymphoma with the T follicular helper cell phenotype (PTCL-TFH) achieve remission, according to a novel study published by Ruan et al in ...
Ibrutinib and Rituximab vs Fludarabine, Cyclophosphamide, and Rituximab in Previously Untreated Patients With CLL
As reported in The Lancet Oncology by Peter Hillmen, MBChB, PhD, and colleagues, an interim analysis of the UK phase III FLAIR trial has shown significantly improved progression-free survival with ibrutinib and rituximab vs fludarabine, cyclophosphamide, and rituximab (FCR) in previously untreated...
Interruption of Adjuvant Endocrine Therapy to Attempt Pregnancy in Women With Breast Cancer
In a study reported in The New England Journal of Medicine, Ann H. Partridge, MD, MPH, and colleagues found that temporary interruption of adjuvant endocrine therapy to attempt pregnancy was not associated with an increased short-term risk of breast cancer events among women with hormone...
Abiraterone Acetate Plus Prednisolone With or Without Enzalutamide in Patients With Metastatic Prostate Cancer Initiating ADT
In an analysis of the final results of two STAMPEDE platform phase III trials reported in The Lancet Oncology, Gerhardt Attard, PhD, and colleagues found that the addition of enzalutamide to abiraterone plus prednisolone did not appear to improve survival outcomes and was associated with worse...
ARTISTRY-7 and ROSELLA: Phase III Trials to Evaluate Novel Agents in Platinum-Resistant Ovarian Cancer
Platinum resistance occurs in almost all patients whose ovarian cancer recurs. Single-agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for effective treatment. At the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...
NOVA: Final Analysis Confirms No Significant Overall Survival Benefit for Maintenance Niraparib in Recurrent Ovarian Cancer
After resolving missing survival data in the phase III ENGOT-OV16/NOVA trial, no statistically significant difference in overall survival was found for patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the PARP inhibitor niraparib, investigators...
Expert Point of View: Amanda Nickles Fader, MD
Amanda Nickles Fader, MD, Professor of Gynecology and Obstetrics, Professor of Oncology, and Vice Chair of Gynecologic Surgical Operations at Johns Hopkins Health System, Baltimore, provided her thoughts on GOG 3026 for The ASCO Post. Dr. Fader applauded the investigators and the Gynecologic...
GOG 3026: Durable Responses With Ribociclib Plus Letrozole in Low-Grade Serous Ovarian Cancer
In patients with recurrent low-grade serous ovarian cancer, treatment with ribociclib plus letrozole was not only active, but led to outcomes that are comparable to those achieved with current agents—with a particularly striking 19-month duration of response—according to Brian M. Slomovitz, MD,...
Expert Point of View: Debra L. Richardson, MD and Joyce F. Liu, MD, MPH
Debra L. Richardson, MD, Associate Professor and Chief of the Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, at the Stephenson Cancer Center, University of Oklahoma, Oklahoma City, discussed the emerging field of antibody-drug conjugates at a session on platinum-resistant ovarian...
Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer
Treatment with the folate receptor alpha (FRα)-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx benefited patients with FRα-high, platinum-resistant ovarian cancer, even after multiple lines of prior therapy, according to an updated analysis of the SORAYA trial presented at the...
Expert Point of View: Rebecca Arend, MD, MSH and Ilaria Colombo, MD
“Endometrial cancer is the most frequently diagnosed gynecologic malignancy in the United States, and it is the only one where the mortality has actually risen over the past 40 years,” noted Rebecca Arend, MD, MSH, Associate Professor at the University of Alabama and Associate Scientist in the...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Highlights of the SGO 2023 Annual Meeting on Women’s Cancer
The sun was out, and the weather was beautiful for the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer held in Tampa, Florida, in March 2023. Participants came from across the world for this second hybrid gathering since the COVID-19 pandemic to share ongoing advances in ...
ASCO Releases Guideline Updates for Stage IV NSCLC With and Without Driver Alterations
ASCO has updated two living guidelines on the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations with the inclusion of new evidence-based treatment recommendations.1,2 Among the updates, the guidelines add the recently approved RAS GTPase family...
Novel Hormone Receptor–Driven Therapies Tackling Endocrine Resistance in Breast Cancer
In hormone receptor–positive metastatic breast cancer, tumors eventually become resistant not only to endocrine blockade but to inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6). This obstacle to successful treatment is being tackled with novel hormone receptor–directed therapies, with the...
Amivantamab Shows Efficacy in Advanced NSCLC With EGFR Exon 20 Insertions
Amivantamab-vmjw, an EGFR and MET bispecific monoclonal antibody, has demonstrated encouraging long-term benefits and consistent efficacy in patients with advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions, according to data presented by Pilar Garrido, MD, PhD, Associate...
CheckMate 816: 3-Year Update Shows Improved Event-Free Survival With Neoadjuvant Nivolumab and Chemotherapy for Resectable NSCLC
The combination of neoadjuvant nivolumab plus chemotherapy continues to demonstrate potential as a standard treatment for patients with resectable non–small cell lung cancer (NSCLC), according to data presented during the European Lung Cancer Congress 2023.1 The 3-year update from the phase III...
CodeBreaK 200: Sotorasib Offers Improved Quality of Life for Patients With Previously Treated NSCLC
The latest research on sotorasib, a targeted therapy for KRAS G12C–mutated non–small cell lung cancer (NSCLC), reveals that patients may experience better quality of life while benefiting from improved clinical outcomes. Analysis of patient-reported outcomes presented during the European Lung...
Expert Point of View: Debra L. Richardson, MD and Joyce F. Liu, MD, MPH
Debra L. Richardson, MD, Associate Professor and Chief of the Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, at the Stephenson Cancer Center, University of Oklahoma, Oklahoma City, discussed the emerging field of antibody-drug conjugates at a session on platinum-resistant ovarian...
Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer
Treatment with the folate receptor alpha (FRα)-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx benefited patients with FRα-high, platinum-resistant ovarian cancer, even after multiple lines of prior therapy, according to an updated analysis of the SORAYA trial presented at the...
Expert Point of View: Margaret K. Callahan, MD, PhD
Formal discussant of the mRNA-4157-P201/KEYNOTE-942 trial, Margaret K. Callahan, MD, PhD, Research Director, Immunotherapeutics Program, Memorial Sloan Kettering Cancer Center, New York, agreed that finding an effective cancer vaccine has been challenging, and she is “cautiously optimistic” about...
Study Shows mRNA-Based Personalized Vaccine Plus Pembrolizumab Active in Melanoma for the First Time
The search for an effective cancer vaccine has been frustrating, but finally there may be light at the end of the tunnel. Adjuvant use of an investigational personalized mRNA vaccine (mRNA-4157) plus the PD-1 inhibitor pembrolizumab improved recurrence-free survival vs pembrolizumab alone in...
Pain Control for Localized Spine Metastases: Stereotactic Radiosurgery vs Conventional Radiotherapy
As reported in JAMA Oncology by Ryu et al, the phase III portion of the NRG Oncology/RTOG 0631 trial showed no benefit in pain relief with use of stereotactic radiosurgery (SRS) vs conventional external-beam radiotherapy (EBRT) in patients with one to three sites of vertebral metastases. Study...
Extension of Adjuvant Anastrozole After Initial Therapeutic Regimen in Postmenopausal Patients With Hormone Receptor–Positive Breast Cancer
In a Japanese phase III trial (AERAS) reported in the Journal of Clinical Oncology, Iwase et al found that an additional 5 years of adjuvant anastrozole after 5 years of anastrozole or tamoxifen followed by anastrozole was associated with improved disease-free survival vs no further anastrozole...
AEGEAN Trial Shows Benefit With Immunotherapy-Based Combination for NSCLC
Patients with treatment-naive resectable non–small cell lung cancer (NSCLC) treated with neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response rates compared with those who received neoadjuvant chemotherapy...
Mansoor R. Mirza, MD, on Endometrial Cancer: New Findings on Dostarlimab-gxly Plus Chemotherapy
Mansoor R. Mirza, MD, of Copenhagen’s Rigshospitalet, discusses phase III data from the ENGOT-EN6-NSGO/GOG-3031/RUBY study, which showed that, compared with carboplatin and paclitaxel alone, dostarlimab-gxly plus carboplatin and paclitaxel increased progression-free survival in patients with...
Immunotherapy/Chemotherapy Combination Prolongs Survival in Advanced Biliary Tract Cancers
The addition of the checkpoint inhibitor pembrolizumab to chemotherapy with cisplatin/gemcitabine as first-line therapy improved overall survival in patients with advanced biliary tract cancer, according to results of the KEYNOTE-966 trial presented at the 2023 American Association for Cancer...
Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Niraparib From the ENGOT-OV16/NOVA Trial
Ursula A. Matulonis, MD, of Dana-Farber Cancer Center discusses the ENGOT-OV16/NOVA study, which initially showed that niraparib maintenance therapy significantly prolonged progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, regardless of germline BRCA mutation...
Addition of Tislelizumab to Chemotherapy in First-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
As reported in The Lancet Oncology by Xu et al, an interim analysis of the phase III RATIONALE-306 trial has shown improved overall survival with the addition of the anti–PD-1 antibody tislelizumab to chemotherapy in the first-line treatment of advanced or metastatic esophageal squamous cell...
Novel Imaging Agent May Help Surgeons Detect Residual Tumor Tissue Following Breast-Conserving Surgery
Researchers have discovered that the investigational optical imaging agent pegulicianine in fluorescence-guided surgery (pFGS) may have been effective at helping surgeons identify and remove residual tumor tissue in patients with breast cancer during breast-conserving surgery, according to a novel...
First-Line Zolbetuximab Plus mFOLFOX6 in CLDN18.2-Positive, HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
As reported in The Lancet by Kohei Shitara, MD, and colleagues, the phase III SPOTLIGHT trial has shown significantly prolonged progression-free and overall survival with the addition of the anti–claudin-18 isoform 2 (CLDN18.2) antibody zolbetuximab to mFOLFOX6 (modified leucovorin [or...
Updated Analysis of Study 309/KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Previously Treated Patients With Advanced Endometrial Cancer
As reported in the Journal of Clinical Oncology by Vicky Makker, MD, and colleagues, an updated analysis of the phase III Study 309/KEYNOTE-775 trial showed overall and progression-free survival benefits with lenvatinib/pembrolizumab vs physician’s choice of chemotherapy among previously treated...
